Merck Signs a Clinical Trial Collaboration with FLX Bio- for a Combination Therapy
Shots:
- The agreement involves assessing of FLXBio’s FLX475 candidate with Merck’s Keytruda (pembrolizumab) in the ongoing P-I/II as an anti-PD-1 therapy in patients with multiple types of cancer
- The study will evaluate efficacy- safety & tolerability of FLX475 as a monothx and in combination with Keytruda in various centers including the US- Australia and Asia
- FLX475 PO is a novel inhibitor of CCR4- while promoting anti-tumor immune response
Ref: FLX Bio | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com